transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: a randomized, double-blind, parallel-group, placebo-controlled study.

Författare och institution:
Håkan Walfridsson (-); Birgitta Johansson (Institutionen för medicin, avdelningen för molekylär och klinisk medicin); Anders Englund (-); Göran Kennebäck (-); Jonas Schwieler (-); Ole Kongstad (-); Karin Wåhlander (Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin); Anders R Malm (-); Nils Edvardsson (Institutionen för medicin, avdelningen för molekylär och klinisk medicin)
Publicerad i:
Clinical drug investigation, 30 ( 7 ) s. 461-71
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
BACKGROUND: AZD0837 is an investigational oral anticoagulant that is bioconverted to its active form, AR-H067637, a selective direct thrombin inhibitor. OBJECTIVES: The objectives of the present study were to investigate if there are any clinically relevant adverse effects of intravenous AZD0837 on cardiac conduction, refractoriness and repolarization, and to study its safety and tolerability. METHODS: In this randomized, double-blind, parallel-group, placebo-controlled study (study code D1250C00026), invasive electrophysiological measurements were performed twice in 30 subjects with a history of, or ongoing, atrial flutter, starting 30 minutes after successful ablation of atrial flutter and then 60 minutes after start of an intravenous infusion of AZD0837. Pre-study warfarin therapy was not an exclusion criterion. The stimulation protocol was performed mainly at 500 and 400 ms drive cycle length. A 12-lead ECG was also recorded before and during AZD0837 infusion. Plasma concentrations of AZD0837 and its metabolites were obtained at predefined timepoints. RESULTS: Measurements were made at baseline and during stable plasma concentrations of the prodrug AZD0837 (mean +/- standard deviation 7.96 +/- 2.38 micromol/L, approximate target of 10 micromol/L), the intermediate metabolite AR-H69927 (1.26 +/- 0.39 micromol/L, target 1-2 micromol/L) and the active direct thrombin inhibitor AR-H067637 (0.35 +/- 0.14 micromol/L, target 0.5-1.0 micromol/L). There were no clinically relevant effects on cardiac conduction (QRS duration, PR interval, His bundle electrogram, Wenckebach point), refractoriness (atrial, atrioventricular and ventricular effective refractory periods) or repolarization (QT, QT interval corrected for heart rate using Fridericia's formula, QRS onset to the top of the T wave [QT(top)], QRS onset to the end of the T wave [QT(end)] or QT(top) - QT(end)). CONCLUSIONS: AZD0837 was well tolerated, and had no clinically relevant effects on cardiac electrophysiology of the target population, either in subjects previously treated with warfarin or in those without previous treatment.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin ->
Adult, Aged, Anticoagulants, adverse effects, pharmacokinetics, Double-Blind Method, Electrocardiography, Electrophysiologic Techniques, Cardiac, Female, Humans, Male, Middle Aged, Pharmaceutical Preparations, adverse effects, Prodrugs, Thrombin, antagonists & inhibitors
Postens nummer:
Posten skapad:
2010-12-09 10:51
Posten ändrad:
2016-06-27 08:20

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007